vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for vTv Therapeutics in a report released on Wednesday, April 9th. HC Wainwright analyst E. Bodnar forecasts that the biotechnology company will earn ($0.73) per share for the quarter. HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. HC Wainwright also issued estimates for vTv Therapeutics' Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.94) EPS, FY2028 earnings at ($3.67) EPS and FY2029 earnings at ($2.70) EPS.
Separately, StockNews.com began coverage on shares of vTv Therapeutics in a research note on Thursday, March 27th. They issued a "sell" rating on the stock.
View Our Latest Analysis on vTv Therapeutics
vTv Therapeutics Stock Performance
Shares of VTVT traded down $0.19 during trading hours on Thursday, hitting $19.17. The company had a trading volume of 745 shares, compared to its average volume of 22,954. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $29.19. The firm has a fifty day moving average price of $17.99 and a 200-day moving average price of $15.82. The stock has a market capitalization of $61.15 million, a price-to-earnings ratio of -4.23 and a beta of 0.81.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.32. The business had revenue of $0.02 million for the quarter.
Institutional Trading of vTv Therapeutics
A number of institutional investors have recently made changes to their positions in VTVT. FMR LLC purchased a new position in shares of vTv Therapeutics in the third quarter worth approximately $2,402,000. Geode Capital Management LLC increased its stake in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock worth $158,000 after buying an additional 1,327 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the fourth quarter valued at about $25,000. Hedge funds and other institutional investors own 17.51% of the company's stock.
About vTv Therapeutics
(
Get Free Report)
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Read More
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
